GENOCEA BIOSCIENCES, INC.
100 Acorn Park Drive
Cambridge, Massachusetts 02149
(617) 876-8191
August 26, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
| | | | | | | | |
| RE: | Genocea Biosciences, Inc. |
| | Registration Statement on Form S-3 (File No. 333-248103) |
| | Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Genocea Biosciences, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-248103) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that it will be declared effective at 4:00 p.m. EST on August 28, 2020, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Thomas Danielski of Ropes & Gray LLP at Thomas.danielski@ropesgray.com or (617) 235-4961.
| | | | | | | | |
|
Very truly yours,
| |
| | |
| GENOCEA BIOSCIENCES, INC.
| |
| | |
| By: | /s/ Diantha Duvall |
| | Diantha Duvall |
| | Chief Financial Officer |
